Impact of asthma controller medications on clinical, economic, and patient-reported outcomes

Mayo Clinic Proceedings

Volumn 84, Issue 8, 2009, Pages 675-684

  Tan, Hiangkiat ^a   Sarawate, Chaitanya ^a   Singer, Joseph ^a   Elward, Kurt ^b   Cohen, Rubin I ^c,d   Smart, Brian A ^e   Busk, Michael F ^f   Lustig, James ^g,h   O'Brien, Jeana D ⁱ   Schatz, Michael ^j  

^a HEALTHCORE INC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e Du Page Medical Group   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h CHILDREN S HOSPITAL OF WISCONSIN   (United States)

ⁱ SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^j KAISER PERMANENTE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; ECONOMIC ASPECT; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

EID: 68149123409     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.8.675     Document Type: Article

References (35)

1. Akinbami L. Asthma prevalence, health care use and mortality: United States, 2003-05. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics Web site. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm. 11-1-2006. Accessed April 24, 2009.
2. Asthma and Allergy Foundation of America. Cost of asthma. 2000. http://www.aafa.org/display.cfm?id=6&sub=63. Accessed August 1, 2008.
3. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1980-1999. MMWR Surveill Summ. 2002;51(1):1-13.
4. US Department of Health and Human Services, National Heart, Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. 8-28-2007. Accessed April 24, 2009.
5. Buhl R, Kardos P, Richter K, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin. 2004;20(8):1209-1220.
6. Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res. 2007;8:46.
7. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999;281(22):2119-2126.
8. Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol. 2004;92(5):523-529.
9. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy. 2002;22(2):166-174.
10. Zeiger RS, Hay JW, Contreras R, et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol. 2008 Apr 12;121(4):885-892.e5. Epub 2008 Mar 4.
11. Allen-Ramey FC, Duong PT, Riedel AA, Markson LE, Weiss KB. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol. 2004;93(4):373-380.
12. Allen-Ramey FC, Anstatt DT, Sajjan SG, Markson LE. Asthma-related health care resource use among patients starting fluticasone or montelukast therapy. Pharmacotherapy. 2005;25(12):1752-1760.
13. O'Connor RD, O'Donnell JC, Pinto LA, Wiener DJ, Legorreta AP. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma [published correction appears in Chest. 2002;122(1):387]. Chest. 2002;121(4):1028-1035.
14. Delea TE, Hagiwara M, Stanford RH, Stempel DA. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther. 2008;30(3):560-571.
15. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol. 2002;109(3):433-439.
16. Allen-Ramey FC, Bukstein D, Luskin A, Sajjan SG, Markson LE. Administrative claims analysis of asthma-related health care utiliza tion for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm. 2006;12(4):310-321.
17. O'Connor RD, Gilmore AS, Manjunath R, Stanford RH, Legorreta AP, Jhingran PM. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives. Curr Med Res Opin. 2006;22(3):453-461.
18. Cai B, Blais L, Suissa S, et al. Distribution of asthma severity and change in severity over time in a general population [abstract]. Presented at: American Lung Association/American Thoracic Society International Conference; San Diego, CA; April 23-28, 1999.
19. Leidy NK, Paramore LC, Watrous M, Doyle J, Zeiger RS. Development of an algorithm for estimating asthma severity from an administrative cost database [abstract PEN3]. Value Health. 1999;2(5):394.
20. Schatz M, Nakahiro R, Jones CH, Roth RM, Joshua A, Petitti D. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care. 2004;10(1):25-32.
21. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14(1):32-38.
22. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med. 1999;160(5, pt 1):1647-1652.
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
24. Chen H, Blanc PD, Chawla A, Hayden ML, Bleecker ER, Lee JH. Assessing productivity impairment in patients with severe or difficult-to-treat asthma: validation of the Work Productivity Activity Impairment - Asthma questionnaire [abstract 705]. J Allergy Clin Immunol. 2006;117(2)(suppl 1):S181.
25. Chen H, Blanc PD, Hayden M, Bleecker ER, Chawla A, Lee JH; TENOR Study Group. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health. 2008;11(2):231-239.
26. Allen-Ramey FC, Duong PT, Goodman DC, et al. Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy Asthma Proc. 2003;24(1):43-51.
27. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics 2002. http://www.nhlbi.nih.gov/ guidelines/archives/epr-2-upd/asthmafullrpt-archive.pdf. 2002. Accessed April 24, 2009.
28. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000;117(2):542-550.
29. Dorais M, Blais L, Chabot I, LeLorier J. Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroids. J Asthma. 2005;42(5):385-393.
30. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma. 2003;40(1):93-101.
31. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(3):487-497.
32. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288-1293.
33. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(2):CD002314.
34. O'Connor RD, Parasuraman B, Roberts C, Leibman C. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities. Ann Allergy Asthma Immunol. 2006;97(2):236-243.
35. 2- agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2006;(4):CD003137.